Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer
Urologic Clinics of North America, ISSN: 0094-0143, Vol: 39, Issue: 4, Page: 547-560
2012
- 8Citations
- 4Usage
- 40Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations8
- Citation Indexes8
- CrossRef3
- Usage4
- Abstract Views4
- Captures40
- Readers40
- 40
Review Description
Antiangiogenic therapy has been successful for the treatment of solid tumors. Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach. © 2012 Elsevier Inc.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0094014312000584; http://dx.doi.org/10.1016/j.ucl.2012.07.010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84867690624&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/23084530; https://linkinghub.elsevier.com/retrieve/pii/S0094014312000584; https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/4668; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=5691&context=smhs_medicine_facpubs; https://dx.doi.org/10.1016/j.ucl.2012.07.010
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know